Biorasi, a CRO that optimizes trial design and delivery for sponsor organizations, is now an associate member organization of the Biosimilars Council, a division of the Generic Pharmaceutical Association (GPhA). This newly minted alliance provides Biorasi with the opportunity to work with the world's leading-edge biosimilar developers, helping to influence policies, form best practices, and promote science-based research and findings related to biosimilar drugs. 

"By interacting with Biosimilars Council member organizations, pharmaceutical and biotechnology manufacturers and stakeholders, legislators and regulatory agencies including the FDA, our team can have an impact on legislation and regulation around clinical developments to foster the rapid approval of biosimilars," said Stephanie Finnegan, president, Divisional Operations for Biorasi. "We are honored to be included in this esteemed group, and we hope to be able to contribute and add value around the clinical development of these molecules."

"We welcome Biorasi as an associate member to the Biosimilars Council," said Bert Liang, chair of the Biosimilars Council and CEO of Pfenex. "Biorasi brings significant experience in clinical research, broadening Council depth and allowing us to connect more deeply with stakeholders across the market in our goal to increase patient access to biosimilars. We look forward to a positive and mutually beneficial relationship with the Biorasi team."